The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents
Open accessAbstract
DNA-damaging agents (DDAs) constitute the backbone of treatment for most human tumors. Here we used the National Cancer Institute Antitumor Cell Line Panel (the NCI-60) to identify predictors of cancer cell response to topoisomerase I (Top1) inhibitors, a widely used class of DDAs. We assessed the NCI-60 transcriptome using Affymetrix Human Exon 1.0 ST microarrays and correlated the in vitro activity of four Top1 inhibitors with gene expression in the 60 cell lines. A single gene, Schlafen-11 (SLFN11), showed an extremely significant positive correlation with the response not only to Top1 inhibitors, but also to Top2 inhibitors, alkylating agents, and DNA synthesis inhibitors. Using cells with endogenously high and low SLFN11 expression and siRNA-mediated silencing, we show that SLFN11 is causative in determining cell death and cell cycle arrest in response to DDAs in cancer cells from different tissues of origin. We next analyzed SLFN11 expression in ovarian and colorectal cancers and normal corresponding tissues from The Cancer Genome Atlas database and observed that SLFN11 has a wide expression range. We also observed that high SLFN11 expression independently predicts overall survival in a group of ovarian cancer patients treated with cisplatin-containing regimens. We conclude that SLFN11 expression is causally associated with the activity of DDAs in cancer cells, has a broad expression range in colon and ovarian adenocarcinomas, and may behave as a biomarker for prediction of response to DDAs in the clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 3×
“(19) reported no significant effect of SLFN11 depletion by shRNA on the response to camptothecin derivatives in sarcoma cell lines.”
BackgroundResultInfluentialTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 1×
“(22) have also recently screened a large panel of cancer cell lines to uncover biomarkers of sensitivity and resistance to cancer therapeutics, but have not identified SLFN11 as a marker of response to Top1 inhibitors.”
BackgroundHematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Bonner, W. M., Redon, C. E., Dickey, J. S., Nakamura, A. J., Sedelnikova, O. A., Solier, S., & Pommier, Y. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2523 · Cited by 1,623
Self-citationCoiffier, B., Thieblemont, C., Van Den Neste, E., Lepeu, G., Plantier, I., Castaigne, S., Lefort, S., Marit, G., Macro, M., Sebban, C., et al. (2010) · Blood · doi:10.1182/blood-2010-03-276246 · Cited by 1,540
DeMatteo, R. P., Ballman, K. V., Antonescu, C. R., Maki, R. G., Pisters, P. W., Demetri, G. D., Blackstein, M. E., Blanke, C. D., von Mehren, M., Brennan, M. F., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60500-6 · Cited by 1,369
Reinhold, W. C., Sunshine, M., Liu, H., Varma, S., Kohn, K. W., Morris, J., Doroshow, J., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1370 · Cited by 887
Self-citationProliferation Marker Ki-67 in Early Breast Cancer
Urruticoechea, A., Smith, I. E., & Dowsett, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.501 · Cited by 837
Induction of a Common Pathway of Apoptosis by Staurosporine
Bertrand, R., Solary, E., O'Connor, P., Kohn, K. W., & Pommier, Y. (1994) · Experimental Cell Research · doi:10.1006/excr.1994.1093 · Cited by 507
Self-citationGuidelines for the Management of Soft Tissue Sarcomas
Grimer, R., Judson, I., Peake, D., & Seddon, B. (2010) · Sarcoma · doi:10.1155/2010/506182 · Cited by 432
CellMiner: a relational database and query tool for the NCI-60 cancer cell lines
Shankavaram, U. T., Varma, S., Kane, D., Sunshine, M., Chary, K. K., Reinhold, W. C., Pommier, Y., & Weinstein, J. N. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-277 · Cited by 400
Self-citationHolbeck, S. L., Collins, J. M., & Doroshow, J. H. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0106 · Cited by 311
Self-citationBussey, K. J., Chin, K., Lababidi, S., Reimers, M., Reinhold, W. C., Kuo, W.-L., Gwadry, F., Ajay, Kouros-Mehr, H., Fridlyand, J., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0155 · Cited by 169
Self-citationYoshihara, K., Tajima, A., Yahata, T., Kodama, S., Fujiwara, H., Suzuki, M., Onishi, Y., Hatae, M., Sueyoshi, K., Fujiwara, H., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009615 · Cited by 160
mRNA and microRNA Expression Profiles of the NCI-60 Integrated with Drug Activities
Liu, H., D'Andrade, P., Fulmer-Smentek, S., Lorenzi, P. L., Kohn, K. W., Weinstein, J. N., Pommier, Y. G., & Reinhold, W. C. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0965 · Cited by 144
Self-citationAntony, S., Agama, K., Miao, Z., Takagi, K., Wright, M. H., Robles, A. I., Varticovski, L., Nagarajan, M., Morrell, A. E., Cushman, M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0938 · Cited by 139
Self-citationWeinstein, J. N. (2012) · Nature · doi:10.1038/483544a · Cited by 121
Bustos, O., Naik, S., Ayers, G. M., Casola, C., Perez-Lamigueiro, M. A., Chippindale, P. T., Pritham, E. J., & de la Casa‐Esperón, E. (2009) · Gene · doi:10.1016/j.gene.2009.07.006 · Cited by 117
Reinhold, W. C., Mergny, J., Liu, H., Ryan, M., Pfister, T. D., Kinders, R. J., Parchment, R. E., Doroshow, J. H., Weinstein, J. N., & Pommier, Y. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3528 · Cited by 70
Self-citationCamptothecin-Based Regimens for Treatment of Ewing Sarcoma: sPast Studies and Future Directions
Wagner, L. M. (2011) · Sarcoma · doi:10.1155/2011/957957 · Cited by 21
Cited by
Correlating chemical sensitivity and basal gene expression reveals mechanism of action
Rees, M. G., Seashore-Ludlow, B., Cheah, J. H., Adams, D. J., Price, E. V., Gill, S., Javaid, S., Coletti, M. E., Jones, V. L., Bodycombe, N. E., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.1986 · Cited by 898
Drugging Topoisomerases: Lessons and Challenges
Pommier, Y. (2013) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 839
Self-citationChemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Gardner, E. E., Lok, B. H., Schneeberger, V. E., Desmeules, P., Miles, L. A., Arnold, P. K., Ni, A., Khodos, I., de Stanchina, E., Nguyen, T., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.006 · Cited by 526
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Dias, M. P., Moser, S. C., Ganesan, S., & Jonkers, J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00532-x · Cited by 505
The present and future of the Cancer Dependency Map
Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C., & Vazquez, F. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-024-00763-x · Cited by 454
Metadata
- Authors
- Zoppoli, G., Regairaz, M., Leo, E., Reinhold, W. C., Varma, S., Ballestrero, A., Doroshow, J. H., & Pommier, Y.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-08-27
- Volume
- 109
- Issue
- 37
- Pages
- 15030-15035
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1972623885
- Cited by
- 369
- References
- 23
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.